Ambisome in Liver Transplant Patients

Stopped early · Phase 4

Conditions studied: Liver Transplantation

In brief

In this study we are trying to find out the amount of a drug called Ambisome in the liver, the blood, the bile and the fatty tissues of the body. This drug is approved for treatment of infections caused by fungus and is known to be effective against most of the fungal infections, which can happen after liver transplantation. By taking small pieces (less than quarter of a teaspoon) of liver and fat during the liver transplant operation, we can measure how much of the drug is concentrated in the liver. After that, we will measure the level of the drug in the blood and in the bile that comes out of a small tube which is inserted into the bile tube as a routine in all liver transplant patients. These measurements will be taken daily for a week and then weekly for another 3 weeks. We are inviting you to take part in this study in order to increase our knowledge of the behavior of this drug so that we can find the most effective treatment to prevent fungal infections in liver transplant patients.

Key facts

Study ID

NCT00161356

Run by

The University of Texas Health Science Center, Houston

People needed

10

Starts

2005-09-01

Expected to finish

2007-12-01

Last updated by the study team

2008-06-23

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All adult liver transplant recipients receiving cadaveric liver transplants

You may not qualify if…

• Patients with choledocho-jejunostomy reconstruction of the biliary tree.
• Children less than 18 years of age
• Patients with known allergy to Amphotericin B.

Where it is running

• Memorial Hermann Hospital — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.